PCYC-1102-CA: BTK Inhibitor Phase I Trial in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

      To access the most up-to-date information on this study,
      please refer to this page at ClinicalTrials.gov.

Official Title

Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia (CLL)

Purpose

The purpose of this study is to establish the safety and optimal dose of orally administered PCI-32765 in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). This study is now closed to enrollment.